title: Topical oral cavity chemoprophylaxis using isotretinoin rinse: A 15-year experience.
abstract: To determine the utility of isotretinoin oral rinses as a method of chemoprevention for recurrent oral cavity squamous cell carcinoma (SCC), carcinoma in situ, and dysplasia.
  
  
  
  Retrospective cohort study.
  
  
  
  One hundred forty-three patients were initially enrolled in the study; however, 18 were excluded due to inability to tolerate therapy. The included patients were classified into four groups. Group 1 included patients with multiple early stage oral cavity lesions following initial resection. Group 2 included patients with SCC in situ after excision. Group 3 included patients with multifocal dysplasia following initial CO2laser ablation. Group 4 included patients with a history of treated oral cavity SCC with new leukoplakia lesions proven to be dysplastic. Fifty-three patients in the control group did not use post-treatment isotretinoin rinses due to various reasons, whereas 72 patients completed therapy. Minimum use of isotretinoin rinses was 12 months, and minimum follow-up was 24 months. During the follow-up period, all recurrences of carcinoma, in situ disease, and dysplasia were noted and compared with a Fisher test of fit. A Bonferroni correction was applied to increase accuracy and strength of comparison.
  
  
  
  Using a Bonferroni correction, the significance threshold was 0.0125. By that cutoff, isotretinoin rinses were found to be associated with lower recurrence in groups 1 and 3 (P = .00014, P = .00002, respectively) but not in groups 2 and 4 (P = .4, P = .3846, respectively).
  
  
  
  Oral isotretinoin as chemoprophylaxis for patients treated for oral cavity squamous cell carcinoma, in situ disease, or dysplasia may be beneficial in decreasing recurrence rate.
  
  
  
  4. Laryngoscope, 127:1595-1599, 2017.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, New York Eye and Ear Infirmary of Mount Sinai, New York, New York.
authors.forename: Sameep
authors.initials: S
authors.lastname: Kadakia
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, New York Eye and Ear Infirmary of Mount Sinai, New York, New York.
authors.forename: Arvind
authors.initials: A
authors.lastname: Badhey
authors.affiliation: Hematology/Oncology Private Practice, Fort Worth, Texas.
authors.forename: Mary
authors.initials: M
authors.lastname: Milam
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Virginia Commonwealth University, Richmond, Virginia.
authors.forename: Thomas
authors.initials: T
authors.lastname: Lee
authors.affiliation: Otolaryngology and Facial Plastic Surgery Associates, Fort Worth, Texas, U.S.A.
authors.forename: Yadranko
authors.initials: Y
authors.lastname: Ducic
mesh_terms: D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage*; D053685:Laser Therapy; D007972:Leukoplakia, Oral / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009067:Mouthwashes; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000517:prevention & control*; D009367:Neoplasm Staging; D011230:Precancerous Conditions / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D055502:Secondary Prevention
chemical_list: D009067:Mouthwashes; D015474:Isotretinoin
keywords: Isotretinoin; chemoprophylaxis; oral cavity cancer